Published in Clin Exp Nephrol on March 18, 2011
Pharmacotherapy of Hypertension in Chronic Dialysis Patients. Clin J Am Soc Nephrol (2016) 0.96
Residual Kidney Function Decline and Mortality in Incident Hemodialysis Patients. J Am Soc Nephrol (2016) 0.92
Epidemiology, diagnosis and management of hypertension among patients on chronic dialysis. Nat Rev Nephrol (2016) 0.76
Proton Pump Inhibitor Use and Magnesium Concentrations in Hemodialysis Patients: A Cross-Sectional Study. PLoS One (2015) 0.75
Strategies for the preservation of residual renal function in pediatric dialysis patients. Pediatr Nephrol (2013) 0.75
K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis (2002) 81.62
Use of single voided urine samples to estimate quantitative proteinuria. N Engl J Med (1983) 3.32
Predictors of loss of residual renal function among new dialysis patients. J Am Soc Nephrol (2000) 2.16
Diuretic use, residual renal function, and mortality among hemodialysis patients in the Dialysis Outcomes and Practice Pattern Study (DOPPS). Am J Kidney Dis (2007) 2.03
Residual renal function and mortality risk in hemodialysis patients. Am J Kidney Dis (2001) 1.52
A double-blind randomized crossover trial of two loop diuretics in chronic kidney disease. Kidney Int (2003) 1.40
Measurement of residual renal function in patients treated with continuous ambulatory peritoneal dialysis. J Am Soc Nephrol (1996) 1.25
The influence of dialysis treatment modality on the decline of remaining renal function. ASAIO Trans (1992) 1.23
Role of diuretics in the preservation of residual renal function in patients on continuous ambulatory peritoneal dialysis. Kidney Int (2001) 0.95
Mechanism of impaired natriuretic response to furosemide during prolonged therapy. Kidney Int (1989) 0.95
Residual renal function: considerations on its importance and preservation in dialysis patients. Semin Dial (2004) 0.94
Evolution of residual renal function in patients undergoing maintenance haemodialysis or continuous ambulatory peritoneal dialysis. Proc Eur Dial Transplant Assoc (1983) 0.89
Response to furosemide in chronic renal insufficiency: rationale for limited doses. Clin Pharmacol Ther (1986) 0.88
Clinical relevance of cytokine production in hemodialysis. Kidney Int Suppl (2000) 0.84
Acute and long-term effects of therapy with high-dose furosemide in chronic hemodialysis patients. Am J Nephrol (1992) 0.83
The effect of dialyzer membrane and etiology of kidney disease on the preservation of residual renal function in chronic hemodialysis patients. ASAIO J (1996) 0.82
Uraemic symptoms, nutritional status and renal function in pre-dialysis end-stage renal failure patients. Nephrol Dial Transplant (2001) 0.82
Clinical implications of biocompatibility in blood purification membranes. Nephrol Dial Transplant (2000) 0.81
Augmenting solute clearance in peritoneal dialysis. Kidney Int (1998) 0.79
The comparison of the diuretic and natriuretic efficacy of continuous and bolus intravenous furosemide in patients with chronic kidney disease. Nephrology (Carlton) (2008) 0.78
Sensitivity of residual nephrons to high dose furosemide described by diuretic efficiency. Eur J Clin Pharmacol (1995) 0.77
Biocompatibility aspects of cellophane, cellulose acetate, polyacrylonitrile, polysulfone and polycarbonate hemodialyzers. Blood Purif (1986) 0.77
Comparison of the effects of muzolimine and furosemide in patients with end-stage renal failure on chronic dialysis. Eur J Clin Pharmacol (1981) 0.76
High-dose torasemide, given once daily intravenously for one week, in patients with advanced chronic renal failure. Clin Nephrol (1997) 0.76
The place of loop diuretics in the treatment of acute and chronic renal failure. Clin Nephrol (1992) 0.76
The influence of 24 h urine sampling on the evaluation of renal dysfunction. Nephrol Dial Transplant (2007) 0.75
Prevalence of abuse in fibromyalgia and other rheumatic disorders at a specialized clinic in rheumatic diseases in Guatemala City. J Clin Rheumatol (2005) 0.81
Gastric juice prostaglandins and peptide growth factors as potential markers of chronic atrophic gastritis, intestinal metaplasia and gastric cancer: their potential clinical implications based on this pilot study. Dig Dis Sci (2011) 0.76
pH-Responsive fluorescent graphene quantum dots for fluorescence-guided cancer surgery and diagnosis. Nanoscale (2017) 0.75